Tissue transglutaminase (tTG 1 or TG2) is distinct from other transglutaminases by its ubiquitous expression, widespread localization, and the ability to bind and hydrolyze guanidine nucleotides (1, 2). In addition to its localization in the cytoplasm and nuclear membranes (3), the protein is also present on the cell surface and in the extracellular matrix (4 -8), despite the lack of a leader sequence or post-translational modifications indicating its processing within the endoplasmic reticulum and the Golgi apparatus (9). More recent studies revealed an important role for tTG in cell adhesion to the extracellular matrix (10 -15). The ability of tTG to stimulate cell adhesion depends on the interaction with ubiquitous and abundant extracellular matrix protein, fibronectin (15). tTG binds to fibronectin with high affinity and 2:1 stoichiometry (16 -18). The 42-kDa domain consisting of modules I 6 II 1,2 I 7-9 represents the only interaction site for tTG on the fibronectin molecule and binds tTG with the same affinity as the whole fibronectin (19). The interaction of cell surface tTG with this part of fibronectin is involved in cell-matrix adhesion (15) and numerous other adhesion-dependent phenomena, including cell migration, matrix assembly, and signaling (20 -23, 26).
Tissue transglutaminase (tTG 1 or TG2) is distinct from other transglutaminases by its ubiquitous expression, widespread localization, and the ability to bind and hydrolyze guanidine nucleotides (1, 2) . In addition to its localization in the cytoplasm and nuclear membranes (3), the protein is also present on the cell surface and in the extracellular matrix (4 -8) , despite the lack of a leader sequence or post-translational modifications indicating its processing within the endoplasmic reticulum and the Golgi apparatus (9) . More recent studies revealed an important role for tTG in cell adhesion to the extracellular matrix (10 -15) . The ability of tTG to stimulate cell adhesion depends on the interaction with ubiquitous and abundant extracellular matrix protein, fibronectin (15) . tTG binds to fibronectin with high affinity and 2:1 stoichiometry (16 -18) . The 42-kDa domain consisting of modules I 6 II 1,2 I 7-9 represents the only interaction site for tTG on the fibronectin molecule and binds tTG with the same affinity as the whole fibronectin (19) . The interaction of cell surface tTG with this part of fibronectin is involved in cell-matrix adhesion (15) and numerous other adhesion-dependent phenomena, including cell migration, matrix assembly, and signaling (20 -23, 26) .
Fibronectin is also a well characterized substrate for enzymatic (protein cross-linking) activity of tTG (5) (6) (7) (23) (24) (25) . High molecular weight covalently cross-linked fibronectin complexes may be formed by either tTG or activated A subunit of factor XIII transglutaminase (FXIIIA (7, 23, 24) ). Nevertheless, the ability of tTG to promote the formation of fibronectin matrix fibrils does not require the cross-linking function of the protein but depends on the interaction with fibronectin (23) .
tTG has also been shown to collaborate with integrins in cell-matrix interactions, acting as high affinity co-receptor for fibronectin (15) . Cell surface tTG directly binds to the ␤1 and ␤3 integrin subunits and forms stable ternary complexes with integrins and fibronectin (15) . Within these complexes, tTG is capable of mediating integrin-fibronectin association, serving as a bridge between integrins and one of their prominent ligands (15) . This unconventional function of tTG in cell-matrix adhesion is independent from its cross-linking activity and is, apparently, unique for this transglutaminase (15, 23) . In addition, the interaction between tTG and fibronectin in the extracellular matrix may define a novel RGD-independent pathway of cell adhesion that inhibits anoikis (26) . Moreover, a recent study has proposed that externalization of tTG may depend on its ability to bind fibronectin (27) . As yet another distinctive function of complex formation between fibronectin and tTG, plasma fibronectin mediates the clearing of tTG from circulation after release of intracellular tTG from damaged erythrocytes (1, 16) .
Despite an obvious significance of the interaction between tTG and fibronectin for cell-matrix interactions, little is known about localization of the fibronectin-binding site(s) on the tTG molecule. Previous work involving limited proteolysis of tTG demonstrated that the NH 2 -terminal 28-kDa fragment of tTG contains the major fibronectin-binding motif(s) (28) . However, the fibronectin-binding site within this part of tTG has not yet been mapped. In the current study, we decided to further explore the issue of localization of the fibronectin-binding site on tTG. The use of chimeric constructs containing swapped domains between tTG and homologous FXIIIA transglutaminase, which is unable to bind fibronectin, as well as deletion mutants of tTG allowed us to localize the fibronectin recognition motif to the NH 2 -terminal ␤-sandwich domain of tTG. Further experiments with deletion mutants of the first domain and synthetic peptides led to mapping the major fibronectin-binding site to the hairpin structure 88 WTATVVDQ-QDCTLSLQLTT 106 , which includes antiparallel ␤ strands 5 and 6 within the first ␤-sandwich domain of tTG. Site-directed mutagenesis of the first domain of tTG showed that Asp 94 and Asp 97 appear to be critical residues for the interaction with fibronectin.
MATERIALS AND METHODS
cDNAs, Vectors, Antibodies, Proteins, and Reagents-cDNAs encoding human endothelial tTG and human FXIIIA have been described previously (9, 29) . pcDNA3.1/Zeo and pcDNA3.1/Myc-HisA/Neo vectors were obtained from Invitrogen. pSwitch-pGene/V5-His dual plasmidinducible system for mammalian expression was from Invitrogen. pGEX4T-1 plasmid for expression of glutathione S-transferase (GST) fusion proteins in Escherichia coli was from Amersham Biosciences. Monoclonal antibody 9E10 against c-Myc was obtained from Abgent (San Diego, CA). Polyclonal affinity-purified antibody against GST was obtained from Molecular Probes, Inc. (Eugene, OR). Monoclonal antibody TG100 against human tTG was obtained from Neomarkers (Freemont, CA). Human red blood cell tTG was purified as described previously (19) . Purified human plasma fibronectin was obtained from Chemicon (Temecula, CA). 42-kDa fibronectin fragment consisting of modules I 6 II 1,2 I 7-9 , was kindly provided by Dr. K. Ingham (American Red Cross). The 42-kDa fragment of fibronectin was immobilized on CNBr-activated Sepharose™ 4B (Amersham Biosciences) at 2 mg/ml resin according to the manufacturer's instructions. GST-agarose and reduced glutathione were from Sigma. Antibiotics neomycin (G418), zeocin, and hygromycin B were obtained from Invivogen (San Diego, CA). Isopropyl-␤-D-thiogalactoside was from Amersham Biosciences. DNase I and lysozyme were from Sigma. Platinum high fidelity TaqDNA polymerase™ and Lipofectamine 2000™ were obtained from Invitrogen. Mouse NIH3T3 fibroblasts were obtained from ATCC (Manassas, VA).
Generation of tTG/FXIIIA Chimeras and tTG Mutants for Expression in Mouse NIH3T3
Cells-A complete list of primers used to produce tTG/FXIIIA chimeras and tTG mutants by PCR mutagenesis is shown in Table I . tTG and FXIIIA cDNAs were initially cloned into pcDNA3.1/Zeo vector. To generate the molecular chimeras where individual domains were swapped between tTG and FXIIIA, a set of overlapping primers (Table II) was used for PCR following an assembly of PCR products and their cloning into HindIII and XhoI sites of the pcDNA3.1/Zeo plasmid. All six chimeric constructs as well as wild type tTG and FXIIIA were then subcloned into pcDNA3.1/Myc-HisA/Neo vector in order to obtain Myc-His tags at the COOH termini. Then the resulting constructs with the COOH-terminal Myc-His tags were subcloned between HindIII and PmeI cloning sites into the pGene/V5-His vector for mifepristone-inducible expression in mammalian cells. Accordingly, the V5-His tags of the pGene/V5-His vector were replaced by Myc-His tags in the resulting constructs.
A similar approach was used to obtain deletion mutants of tTG as well as tTG/FXIIIA chimeras where the NH 2 -terminal amino acid sequences were swapped between the two proteins. The PCR primers for generation of these constructs are presented in Table III . Again, the final PCR products were inserted into the pcDNA3.1/Myc-HisA/Neo vector for fusion with COOH-terminal Myc-His tags, and the resulting Forward primers
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constructs were subcloned into the pGene/V5-His vector for inducible expression. The correct sequences of the resulting tTG mutants were confirmed by DNA sequencing. Mammalian Cell Culture, Transfection, and Inducible Expression of tTG Mutants-NIH3T3 cells were routinely grown in DMEM containing 10% fetal bovine serum. NIH3T3 cells expressing negligible levels of endogenous tTG were initially transfected with pSwitch vector using Lipofectamine 2000™, and the resulting transfectants were selected with 100 g/ml hygromycin. The selected populations of NIH3T3/pSwitch cells were then transfected with pGene/Myc-His plasmids encoding tTG deletion mutants or tTG/FXIIIA chimeras. The resulting populations of double transfectants were selected with 100 g/ml zeocin. To induce expression of tTG deletion mutants or tTG/FXIIIA chimeras, the transfectants were treated for 24 h with 10 Ϫ10 M mifepristone. The expression levels of tTG mutants were determined using SDS-PAGE with 20 g of total cell lysates and immunoblotting with anti-Myc antibody.
Generation of the tTG First Domain Mutants for Expression in E. coli-A set of deletion mutants of the first domain of tTG was generated based on the tTG-(1-140) construct expressed in the pGene/ Myc-His vector. The insert encoding the first domain of tTG was initially subcloned into pGEX4T-1 plasmid for expression as glutathione S-transferase (GST) fusion proteins in E. coli. Deletion mutants of the first domain of tTG were made by PCR mutagenesis as well, using the sets of primers shown in Table IV . For the deletion mutants where NH 2 -terminal or COOH-terminal amino acid sequences were truncated, sets of two terminal primers, both of which contained incorporated cloning sites, were used. For one deletion mutant where the central portion of the first domain was removed, a set of two terminal primers and two overlapping primers (Table IV) To induce expression of GST fusion proteins in E. coli, the log phase bacterial cultures were grown for 5 h at 27°C in the presence of 20 M isopropyl-␤-D-thiogalactoside. GST fusion proteins were purified using glutathione-agarose beads according to the manufacturer's instructions. The expression levels of all of the mutants appeared similar, with a typical yield ϳ1.2-2 mg of the purified protein isolated from 1 liter of E. coli culture. The lack of proteolytic degradation and the purity of the first tTG domain mutants were verified by SDS-PAGE.
Protein Concentration Determination-Concentrations of purified GST-tTG-(1-140) fusion protein and its individual point mutants M1-M5 were determined by two independent methods. First, protein concentrations were determined spectrophotometrically using extinction coefficients (E 280,1% ) calculated from the amino acid composition by the following equation:
where W, Y, and S-S represent the number of Trp and Tyr residues and disulfide bonds, respectively, and M represents molecular mass (30) . Second, protein concentrations were measured using a Micro BCA protein assay reagent kit (Pierce) with BSA and human IgG as external protein standards. The two methods resulted in protein concentrations differing by less than 10%.
In Vitro Binding Assays-To test the interaction of tTG/FXIIIA chimeras and tTG mutants with immobilized 42-kDa fragment of fibronectin, 5 ϫ 10 5 NIH3T3 transfectants were induced for 24 h with mifepristone to trigger expression of the proteins of interest. Then the cells were lysed in 1 ml of radioimmune precipitation buffer (50 mM Tris/Cl, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) containing protease inhibitors 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 10 g/ml aprotinin, 10 g/ml pepstatin. Cell lysates were cleared by centrifugation (15,000 rpm, 30 min, 4°C), and supernatants were used for binding with the 42-kDa fibronectin fragment immobilized on Sepharose beads. After a 1-h incubation of cell lysates at 4°C on rotator with 100 l of the bead slurry containing ϳ20 g of immobilized 42-kDa fragment, the beads with bound material were extensively washed with radioimmune precipitation buffer, and the bound proteins were analyzed by SDS-PAGE and immunoblotting with anti-Myc antibody. A similar method was used to study the binding of purified mutants of the first domain of tTG, with immobilized 42-kDa fragment. In this case, bound proteins were detected by immunoblotting with anti-GST antibody.
In reverse in vitro binding experiments, purified fibronectin in solution (10 g/ml in radioimmune precipitation buffer) was tested for binding to the mutants of the first domain of tTG immobilized on glutathione-agarose (20 -25 g of purified GST fusion proteins were bound to 50 l of the beads). After incubation for 1 h at 4°C and subsequent extensive washing of the beads with radioimmune precipitation buffer, bound fibronectin and immobilized tTG mutants were analyzed by SDS-PAGE and detected by staining protein bands with Coomassie Blue.
Peptides-The peptides corresponding to human tTG sequences 2 
(P3s), were synthesized by SynPep (Dublin, CA) using an Applied Biosynthesis model 430 peptide synthesizer. All of the peptides had amidated COOH termini. Authenticity and purity (Ͼ95%) of the peptides were confirmed by high performance liquid chromatography and mass spectrometry. Solid Phase Binding Assays-Solid phase binding was performed in microtiter plates using ELISA. Microtiter plate wells (Fisher) were coated overnight with 100 l/well of the 42-kDa fragment of fibronectin at 20 g/ml in 0.1 M Na 2 CO 3 , pH 9.5 (coating buffer). The wells were then blocked with 1% BSA in TBS. After washing with TBS containing 0.05% Triton X-100, the peptides P1-P4 and purified GST fusion protein containing the first domain of tTG, GST-tTG-(1-140), all in the same buffer, were added to the wells at 0.1-100 M concentrations and incubated for 1 h at 22°C. Then purified human red blood cell tTG was added to the same wells to a final concentration of 2.5 nM and incubated in the wells for 1 h at 22°C. Bound tTG was measured by reaction with monoclonal antibody TG100 and peroxidase-conjugated goat antimouse polyclonal antibodies. A TMB Microwell Peroxide Substrate (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) was added to the wells, and the amount of bound tTG was determined spectrophotometrically at 450 nm.
Cell Adhesion and Spreading Assays-24-well tissue culture plastic plates (Midwest Scientific, St. Louis, MO) were coated with a 20 g/ml concentration of the 42-kDa fibronectin fragment in TBS, for 16 h at 4°C, and then blocked with 10 mg/ml BSA. Peptides P1-P4 and the GST fusion protein containing the purified first domain of tTG, GST-tTG-(1-140), were added to some wells at 100 M in serumfree DMEM and incubated in the wells for 1 h at 37°C. For adhesion experiments, NIH3T3 transfectants overexpressing wild type tTG were labeled overnight with 20 Ci/ml Tran 35 S-Label (MP Biomedicals, Irvine, CA). After detachment by EDTA treatment, 5 ϫ 10 4 35 S-labeled cells were plated into each well in serum-free DMEM containing 5 mg/ml BSA and allowed to adhere for 15 min or 60 min at 37°C either with or without peptides P1-P4 and GST-tTG-(1-140). Adherent cells were washed three times with PBS and lysed in 1% SDS. The bound radioactivity was counted in a Beckman LS 3801 scintillation counter and converted into the number of adherent cells by referring to the levels of 35 S incorporation/10 3 cells. To determine the effects of different peptides on cell spreading, glass coverslips within 24-well tissue culture plastic plates were coated with a 20 g/ml concentration of the 42-kDa fragment of fibronectin and then blocked with 10 mg/ml BSA. Before cell plating, some coverslips were preincubated with 100 M peptides P1-P4 or the GST-tTG-(1-140) fusion protein in serum-free DMEM. 2 ϫ 10 4 NIH3T3 cells overexpressing wild type tTG were plated on coated glass coverslips for 3 h in serum-free DMEM with 5 mg/ml BSA at 37°C. At the end of this incubation, cells were briefly washed with DMEM, fixed with 3.7% paraformaldehyde, stained with Coomassie Blue, destained, and photographed.
Surface Plasmon Resonance (SPR) Studies-Binding parameters for the interaction of the GST fusion protein containing the first domain of tTG, GST-tTG-(1-140), and its point mutants M1-M3, with the 42-kDa fragment of fibronectin, were determined by using the Biacore 3000 SPR-based biosensor (BIAcore AB, Uppsala, Sweden), which measures association/dissociation of proteins in real time. The 42-kDa fragment of fibronectin was immobilized to the CM5 sensor chip using the amine coupling kit (BIAcore AB) according to the manufacturer's instructions. The 42-kDa fragment was immobilized at 20 g/ml in 10 mM sodium acetate, pH 4.5. Biosensor surfaces were coupled to final response values of ϳ1000 response units.
Binding experiments were performed in HBS-P buffer (BIAcore AB) at 10 l/min flow rate. The GST-tTG-(1-140) fusion protein and the M1-M3 point mutants of the first tTG domain were injected in duplicate at 75-600 nM concentrations in three separate experiments, and the association between immobilized 42-kDa fibronectin fragment and the added proteins was monitored as the change in the SPR response. The dissociation was measured upon replacement of the ligand solution for the buffer without ligand. To regenerate the chip surface, complete dissociation of the complex was achieved by adding a solution containing 20 mM NaOH and 1 M NaCl for 1 min followed by reequilibration with the binding buffer. Experimental data were analyzed using BIAevaluation 3.1 software supplied with the instrument. Briefly, kinetic constants, k a and k d , were estimated by global analysis of the association/dissociation curves to the 1:1 Langmurian interaction model (31) .
RESULTS

A Major Interaction Site for Fibronectin Is Located within the
First Domain of tTG-Previously, it was shown that the fibronectin-binding site on tTG is localized within the NH 2 -terminal 28-kDa proteolytic fragment of tTG (28) . The 28-kDa proteolytic fragment contains both the entire first and a significant part of the second domains of tTG (28, 32) . Hence, we employed molecular mutagenesis approach to map the fibronectin-binding site on the tTG molecule (Fig. 1) . Since FXIIIA, a homologue of tTG, does not interact with fibronectin (1, 15), we generated six molecular chimeras where individual domains were swapped between tTG and FXIIIA (Fig. 1A) . The tTG/FXIIIA chimeric constructs containing COOH-terminal Myc-His tags were transfected into the NIH3T3 cell line, and their expression was induced by mifepristone. Immunoblotting of cell lysates with anti-Myc monoclonal antibody showed that all of the chimeric constructs were expressed at comparable levels in these transfectants with no signs of proteolytic degradation (Fig. 1B) . We tested interaction of the tTG/FXIIIA chimeras with the 42-kDa fibronectin fragment immobilized on Sepharose beads (Fig. 1C) . Only tTG and three chimeras con- 
Fibronectin-binding Site on Tissue Transglutaminase
taining the first domain of tTG displayed binding to the 42-kDa fragment of fibronectin, whereas FXIIIA and the other three chimeras lacking the first domain of tTG were unable to interact with the fibronectin fragment. Therefore, the first ␤-sandwich domain of tTG contains the major site for the interaction with fibronectin.
The Core of the First tTG Domain but Not the NH 2 -terminal Tail Is Essential for the Interaction with Fibronectin-Deletion of the entire first domain or its parts within the Myc-His tagged tTG construct led to generation of unstable mutants susceptible to proteolytic degradation (data not shown). Therefore, to test whether the first domain of tTG is sufficient for the interaction with fibronectin, three tTG deletion mutants containing only the first domain (tTG- (1-140) ), the first and second domains (tTG- (1-460) ), and the first, second, and third domains (tTG-(1-592)), were produced ( Fig. 2A ). An earlier experiment showed that the removal of seven NH 2 -terminal amino acids of tTG with endoproteinase Glu-C affected its ability to interact with fibronectin when probed by ligand blotting of the SDSdenatured tTG (28) , but no direct binding of the synthetic peptide representing tTG amino acids 1-12 to fibronectin could be demonstrated in solution. 2 In order to examine the question whether the NH 2 -terminal sequence is essential for binding fibronectin, we produced a tTG deletion mutant, tTG-(16 -687), where the first 15 amino acids were deleted ( Fig. 2A) . These residues comprise a flexible NH 2 -terminal tail that was not resolved in the crystal structure of tTG (32) . In addition, two more chimeric constructs with the nonhomologous NH 2 -terminal tail sequences swapped between tTG and FXIIIA (FXIIIA-(1-59)tTG-(16 -687) and tTG-(1-15)FXIIIA-(60 -731)) were generated ( Fig. 2A) . All of these constructs bearing COOHterminal Myc-His tags were transfected in NIH3T3 cells and expressed after induction with mifepristone (Fig. 2B) . As judged by blotting with anti-Myc antibody, all of the constructs appeared relatively stable with only traces of proteolytic degradation. The tTG-(1-140) construct as well as two other tTG deletion mutants containing the first tTG domain bound to the immobilized 42-kDa fragment of fibronectin as efficiently as the whole tTG (Fig. 2C) . Importantly, the removal of 15 NH 2 -terminal amino acids did not significantly decrease the binding of the tTG-(16 -687) mutant to the 42-kDa fibronectin fragment. Likewise, the tTG mutant containing the nonhomologous NH 2 -terminal sequence of FXIIIA instead of the 15 NH 2 -terminal amino acids of tTG (FXIIIA-(1-59)tTG-(16 -687)), interacted strongly with the fibronectin fragment. In contrast, no binding to the 42-kDa fragment was detected for the FXIIIA mutant containing the 15 NH 2 -terminal amino acids of tTG (tTG-(1-15)FXIIIA-(60 -731)). These results indicate that the first domain of tTG is necessary and sufficient for fibronectin binding. Also, they point to a key role of the core of the first tTG domain (amino acids 16 -140), whereas the NH 2 -terminal sequence of tTG (amino acids 1-15) appears dispensable for this interaction.
The Fibronectin-binding Site on tTG Is Located within the COOH-terminal Half of the First Domain-To further advance mapping of the fibronectin-binding site on the tTG molecule, a set of deletion mutants of the first domain of tTG was designed based on the published crystal structure of human tTG (32) in order to maximize preservation of secondary structure elements within the first domain of the protein (Fig. 3, A and B;  mutants A-H) . Expression of these tTG deletion mutants as GST fusion proteins in E. coli and subsequent purification under nondenaturing conditions produced GST fusion proteins with expected molecular mass and no or little proteolytic degradation (Fig. 3C) . Then the mutants were tested for their ability to interact with fibronectin (Fig. 3, D and E) . Both affinity binding experiments with the purified soluble GST fusion proteins and immobilized 42-kDa fragment of fibronectin (Fig. 3D) and analyses of interaction of soluble fibronectin with the mutant GST fusion proteins immobilized on glutathione-agarose (Fig. 3E) indicated that amino acids 1-80 of tTG did not contribute significantly to its interaction with fibronectin. Accordingly, the mutant E containing amino acids 81-140 of tTG retained a full binding capacity, whereas the mutant F containing residues 1-96 displayed only a weak binding to fibronectin. Therefore, the major binding site for fibronectin is localized within amino acids 81-140 of tTG.
Antiparallel ture of the first ␤ sandwich domain of tTG revealed eight ␤ strands with the most prominent antiparallel ␤ strands 5 and 6 comprising a hairpin extended far from the globular domain (32) . A set of peptides P1-P4 was synthesized, representing the NH 2 -terminal tail of tTG (P1), the ␤5/␤6 hairpin (P3), and two flexible loops located adjacent to the antiparallel ␤ strands 5 and 6 but not resolved in the crystal structure of the first domain (P2 and P4) (Fig. 4A) (32) . Next, in vitro binding experiments were performed with the 42-kDa fragment of fibronectin immobilized on plastic wells and purified human tTG in the presence of these peptides. When used at 100 M, the peptides P1, P2, and P4 did not affect the interaction of tTG with the 42-kDa fragment (Fig. 4B) . In contrast, the P3 peptide spanning the antiparallel ␤ strands 5 and 6 inhibited this interaction by ϳ80% at 100 M. A concentration-dependent effect of the P3 peptide on the interaction between tTG and the 42-kDa fragment of fibronectin was characterized by a halfmaximal inhibition (IC 50 ) of ϳ4 M, whereas a scrambled version of the P3, P3s, had essentially no inhibitory effect (Fig.  4C) . Hence, the hairpin structure, which includes the residues 88 WTATVVDQQDCTLSLQLTT 106 forming the antiparallel ␤ strands 5 and 6 of the first domain, is directly involved in formation of the binding site for fibronectin.
The P3 Peptide Inhibits Adhesion and Spreading of Cells on the 42-kDa Fibronectin Fragment-Previous
studies from our laboratory demonstrated that adhesion, spreading, and migration of fibroblasts, macrophages, and glioma cells on the 42-kDa fragment of fibronectin depends on cell surface tTG (15, 20, 21) . Since the P3 peptide was found to strongly interfere 
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with the interaction of tTG and fibronectin in vitro, we examined whether it also affects adhesion and spreading of tTGexpressing NIH3T3 cells on the 42-kDa fibronectin fragment (Fig. 5, A and B) . In static adhesion assays, the number of adherent cells at 15 and 60 min after plating decreased by ϳ75-80% in the presence of a 300 M concentration of the P3 peptide and by ϳ85-90% with a 20 M concentration of the GST-tTG-(1-140) fusion protein. In contrast, no inhibitory effect on cell adhesion was seen with the peptides P1, P2, and P4.
In agreement, 3 h after plating, the cells were unable to spread on the 42-kDa fragment of fibronectin in the presence of the P3 peptide or the GST-tTG-(1-140) fusion protein, whereas three other peptides had essentially no effect on cell spreading. In agreement with our previous findings (15, 21) , no adhesion and spreading on the 42-kDa fragment was detected with cells lacking surface tTG (data not shown). Thus, the P3 peptide spanning the antiparallel ␤ strands 5 and 6 of the first domain specifically and potently inhibits adhesion and spreading of tTG-expressing cells on the 42-kDa fragment of fibronectin.
tTG Residues Asp 94 and Asp 97 in the ␤5/␤6 Hairpin Are Critical for the Interaction with Fibronectin-Earlier studies indicated that charged amino acids may have a key role in the interaction of tTG with fibronectin (18, 19) . Having defined the functional sequence on tTG for binding fibronectin, we employed site-directed mutagenesis in a search for tTG residues critical for this interaction. Based on the crystal structure of tTG, most residues comprising the ␤5/␤6 hairpin appear to be exposed on the surface of the first domain (32) . Given the proposed involvement of charged residues in the association with fibronectin, we chose to substitute Asp 94 , Asp 97 , or both Asp 94 and Asp 97 , with Ala, thereby generating M1-M3 point mutants of the GST-tTG-(1-140) fusion protein (Fig. 6A) . All of the mutants were expressed in E. coli and purified on glutathione-agarose (Fig. 6B) .
Finally, the interaction of the GST-tTG-(1-140) fusion protein and the M1-M3 point mutants with immobilized 42-kDa fragment was studied in real time using SPR (Fig. 6, C and D) . The GST-tTG-(1-140) fusion protein exhibited a dose-dependent binding to the 42-kDa fragment of fibronectin immobilized on a BIAcore sensor chip (Fig. 6C) . The global fitting analysis (see "Materials and Methods") of the SPR-detected binding curves obtained at different concentrations of GST-tTG-(1-140) gave the K d value of 180 Ϯ 12 nM (Fig. 6C) . To compare affinities of the GST-tTG-(1-140) fusion protein and the M1-M3 mutants with fibronectin, the interaction of these proteins with the 42-kDa fibronectin fragment was studied using the SPR method (Fig. 6D) . As shown for the proteins at 600 nM, (Fig. 6D and Table VI) . Moreover, the double mutant M3 (D94A/D97A) exhibited a drastically lower affinity for the 42-kDa fragment with the estimated K d values of ϳ46 Ϯ 16 M. It should be noted, however, that mutation of other residues within the ␤5/␤6 hairpin, such as Cys 98 , did not distinctly decrease the affinity of tTG for the 42-kDa fibronectin fragment (data not shown). Therefore, the residues Asp 94 and Asp 97 within the ␤5/␤6 hairpin appear critically important for the interaction of tTG with fibronectin.
DISCUSSION
In the present study, we analyzed the molecular basis for the recognition of fibronectin by tTG. We showed that the NH 2 -terminal ␤-sandwich domain of tTG, tTG-(1-140), is necessary and sufficient for this interaction (Figs. 1 and 2) . In contrast to the previously published studies (27, 28) , we found that the first 15 amino acids of tTG comprising its NH 2 -terminal tail are dispensable for fibronectin binding (Fig. 2) . Hence, we searched for functional sequences within the first domain of tTG involved in the interaction with fibronectin. Our analyses with deletion mutants of the first domain revealed that the functional sequence(s) is located within the amino acids 81-140 of the protein (Fig. 3) . Further experiments with synthetic peptides corresponding to various regions of the first domain demonstrated that the major functional sequence for the interaction with fibronectin is present within the ␤5/␤6 hairpin consisting of the antiparallel ␤ strands 5 and 6 of the first domain (Fig. 4) . The peptide P3, 88 WTATVVDQQDCTLSLQLTT 106 , encompassing the ␤5/␤6 hairpin but not its scrambled analog, P3s, was able to potently inhibit the interaction of tTG with fibronectin, whereas peptides corresponding to other regions of the first domain did not show any significant inhibitory activity. In agreement with these results, the same peptide efficiently decreased tTG-dependent adhesion and spreading of cells on the 42-kDa domain of fibronectin consisting of modules I 6 II 1,2 I 7-9 , which interacts with tTG (15, 19) but does not contain any integrin-binding sites or any known motifs for association with other cell adhesion receptors (Fig. 5) (25) . Therefore, our results indicate that the ␤5/␤6 hairpin of the first domain represents the major recognition site on the tTG molecule for the interaction with fibronectin (Fig. 7) . In this regard, it is worth mentioning that this hairpin forms a prominent "finger" which is extended well beyond the globular first domain with its tip located aside from any other parts of the tTG molecule (Fig. 7A) (32) . Probably, this lack of structural constraints makes the ␤5/␤6 hairpin well positioned for the interaction with the extremely large fibronectin molecule.
To confirm and extend these findings, we set out to identify residues within this sequence that contribute significantly to fibronectin binding. Importantly, single point mutations of either Asp 94 or Asp 97 to Ala decreased markedly the affinity of the GST-tTG-(1-140) fusion protein for the 42-kDa fragment. (Fig. 4) and point mutants ( 
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Moreover, a substitution of both Asp 94 and Asp 97 with Ala in the double mutant caused a further steep decrease in the affinity with the 42-kDa fibronectin fragment, demonstrating a synergistic effect of these mutations on fibronectin binding. At the same time, replacement of the adjacent Cys 98 in the antiparallel ␤ strands 5 and 6 with Ala had very little if any effect on this interaction. Therefore, Asp 94 , located close to the middle of the ␤5 strand and Asp 97 , positioned at the very tip of the ␤5/␤6 hairpin within the NH 2 -terminal domain, function as tTG residues involved in fibronectin binding (Fig. 7B) .
Alignment of putative fibronectin-binding sequences for tTG from different species of vertebrates showed that both Asp 94 and Asp 97 appeared well conserved among six mammalian tTGs (Fig. 8A) . This underscores the importance of these two residues for the interaction of mammalian tTGs with fibronectin. However, a weaker binding to human 42-kDa fibronectin fragment of the guinea pig compared with human tTG (16 -18) points to a possible involvement of other residues within the ␤5/␤6 hairpin besides Asp 94 and Asp 97 in this interaction. Interestingly, the putative fibronectin-binding sequence also appeared quite divergent in the chicken tTG, with both Asp residues being replaced. This agrees well with the inability of chicken tTG to bind human fibronectin (33) and suggests that the structural motifs for the tTG-fibronectin association are somewhat different in the avian proteins.
Sequence alignment of human tTG with seven other transglutaminases revealed that within the ␤5/␤6 hairpin, only the Trp 88 and Ala 90 residues appear conserved among all eight family members, whereas there is very little or no homology in the remaining parts of this structural element (Fig. 8B) (29) . This appears to be in good agreement with the unique ability of tTG to interact with fibronectin, not shared by other members of the transglutaminase family (1, 2, 15) .
It has to be noted that the apparent K d for the interaction of the GST-tTG-(1-140) and immobilized 42-kDa fragment in our SPR experiments (ϳ180 nM) appeared to be significantly higher than that previously reported for binding of native purified tTG to the same fibronectin fragment in solid phase binding experiments (ϳ8 -10 nM) (19) . This discrepancy may be attributed to a difference in the methods of analysis of the interaction between tTG and fibronectin. Also, since the full-length GST-tTG fusion protein interacted with fibronectin slightly weaker (K d ϳ24 nM; data not shown) than purified native tTG, a partial interference of the GST portion of the GST-tTG-(1-140) fusion protein with this association cannot be excluded. In addition, our data with the tTG deletion mutants indicated that the first domain by itself (tTG-(1-140)) binds to the immobilized 42-kDa fibronectin fragment somewhat less strongly than the first and second domain together (tTG-(1-460); see Fig. 2, B and C) . This observation suggests that the second (catalytic) domain of tTG, which by itself does not show any detectable binding capacity, still may stabilize the interaction of the adjacent first domain with fibronectin.
The involvement of tTG in cell-matrix adhesion is based on its ability to interact with fibronectin and simultaneously bind the ␤1 or ␤3 integrin subunits (1, 2, 15) . Previous analyses of stable integrin-tTG-fibronectin ternary complexes isolated from cultured cells showed that the tTG molecule can serve as a bridge between integrins and one of their prominent matrix ligands, fibronectin (15) . The interaction site(s) for ␤1 integrins on tTG has not yet been mapped. However, our preliminary results show that the NH 2 -terminal domain of tTG is required for this interaction. 3 It remains to be explored whether the integrin-and fibronectin-binding sequences overlap within the first domain of tTG or each tTG monomer can simultaneously interact with the other two molecules. Meanwhile, even in the case of overlapping binding sites for integrins and fibronectin on the NH 2 -terminal domain, dimerization of tTG analogous to that demonstrated in the crystal structure (32) should allow formation of the ternary complexes.
Recent studies from this and other laboratories showed that the interaction of cell surface tTG with fibronectin contributes significantly to cell-matrix association and affects cell adhesion, migration, and assembly of fibrillar fibronectin matrices (12-15, 20 -23, 26) . Delineation of the fibronectin-binding site on tTG will enable us to precisely examine the role of this protein in the interactions of cells with fibronectin.
